HeartWare International Reports Third Quarter Revenues of $7...(2009 2008 ...),Health

Date:11/4/2009

2009 2008 ----------- ---------- (unaudited) ASSETS Current assets: Cash and cash equivalents $31,421 $20,804 Accounts receivable 6,138 244 Inventories, net 8,008 3,508 Prepaid expenses and other current assets 1,140 1,062 ----- ----- Total current assets 46,707 25,618 Property, plant and equipment, net 3,914 3,609 Other intangible assets, net 1,118 823 Deferred financing costs, net 3,603 - Restricted cash 288 288 --- --- Total assets $55,630 $30,338 ======= ======= LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $3,404 $699 Accrued expenses and other current liabilities 2,496 2,883 ----- ----- Total current liabilities 5,900 3,582 Long-term convertible debt 4,000 - Derivative instrument 6,115 - Commitments and contingencies Stockholders' equity: Common stock, $.001 par value; 25,000,000 shares authorized; 10,316,809 and 8,866,702 shares issued and outstanding at September 30, 2009 and December 31, 2008, respectively 10 9 Additi
'/>"/>

SOURCE HeartWare International, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Presentation of HeartWare Clinical Results
2. HeartWare International Clinical Trial Shows 90% Survival at 180 Days
3. U.S. FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U.S. Bridge-to-Transplant Clinical Trial
4. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
5. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
6. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
9. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
10. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
11. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference